We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Afriag | AFRI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.085 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.085 | 0.085 |
| Top Posts |
|---|
Posted at 13/4/2021 07:46 by the chairman elect 3 April 2021Apollon Formularies PLC (“Apollon̶ ADMISSION TO TRADING ON AQSE GROWTH MARKET AND FIRST DAY OF DEALINGS CONSENT FROM APOLLON LIMITED SHAREHOLDERS Apollon Formularies PLC (AQSE: APOL) is pleased to announce that admission of the Company's ordinary shares to trading on AQSE Growth Market ("Admission") will take place and dealings will commence at 8.00 am GMT today, Tuesday 13 April 2021, under the ticker “APOL” (ISIN: IM00BJ0LRD77). Highlights Successful £2.5 million fundraising at 5p which was oversubscribed. Peterhouse acted as corporate broker Apollon’s Jamaican affiliate has a federal licensing framework that allows it to operate a fully integrated seed to patient business Apollon’s Jamaican affiliate’s processing laboratory based in Negril, Jamaica is able to produce high volumes of full spectrum medical cannabis oil, using both high and low THC cannabis plant material Apollon’s Jamaican affiliate’s R&D licence allows its medical team to undertake full spectrum, medically supervised treatments and conduct clinical trials as approved by the Jamaican Ministry of Health Proceeds will be used to, among other things, scale up operations, identify international customers for its high quality oils, commercialise development of its 3D-printer for production of medical cannabis sublingual, oral and suppository products, and continue its R&D in an effort to develop the Apollon product line range of both high and low THC oils and products, expand cultivation and processing of its formulations and increase capacity and international export for its medical cannabis treatments The Company notes that the Vendors of Apollon Limited, voted their shares 100% (excluding those shares already owned by the Company) in favour of the Offer. Dr Stephen Barnhill, CEO of Apollon Formularies Plc, says: "Today we achieved an important milestone and I am proud of the team and the work that has been done to get us here. With a full listing on the AQSE Growth Market, we will now set about to scale up our already impressive operation. “Apollon currently holds a unique position as one of the few listed European companies able to undertake medically supervised treatments inclusive of utilising THC to allow for drug discovery and the development of additional formulations to add to our already successful product line range. This listing in London offers investors the opportunity to be a part of a full spectrum medical cannabis company as it moves to implement its international growth strategy. This is an exciting time for our Company, as well as the entire medical cannabis space across the UK and Europe, and we look forward to updating the market as we continue to deliver upon our strategy.” About Apollon Apollon Formularies plc is an international medicinal cannabis pharmaceutical company. Apollon Formularies Jamaica Limited (“AFJ”) is the principal entity with which Apollon has an interest. AFJ is a government licenced medicinal cannabis company incorporated in Jamaica and is licensed and approved to cultivate, process, perform research and development for, and sell medical cannabis therapeutic products. AFJ is currently producing pharmaceutical, nutraceutical, and other medical cannabis related products, including 3D printed sublingual, suppositories and capsules. It was established to advance the current significant commercial opportunities in the legal medical cannabis markets globally. Key strengths AFJ operates at the Federal level in Jamaica and holds a suite of licences that allows it to be a fully operational, vertically leveraged medical cannabis enterprise AFJ’s cultivation licence allows it to develop and grow strains of cannabis for medicinal uses AFJ’s Processing Laboratory is based in Negril, Jamaica, and is able to produce full spectrum medical cannabis oil, which is inclusive of THC AFJ’s R&D licence allows it to undertake initiatives for drug discovery using THC and other cannabinoids to develop a range of products that are backed by clinical data AFJ’s science and medical professionals have developed and use proprietary artificial intelligence to identify compounds and develop formations that can be productized, tested, clinically trialed, and then used on various illnesses under medical supervision AFJ owns and operates a therapeutic medical cannabis dispensary onsite in Jamaica AFJ has created and/or obtained, identified, developed, and commercialised several proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products AFJ’s vertically licenced, full spectrum medical cannabis framework gives the Company the unrivalled ability to perform medically supervised treatments The Directors of the Company accept responsibility for the contents of this announcement. - Ends - For additional information please contact: Apollon Formularies Tel: +44 207 907 9314 Stene Jacobs stene@apollon.org.uk Peterhouse Capital Limited (Corporate Adviser) Tel: +44 207 220 9795 Guy Miller gm@peterhousecapital Blytheweigh (Financial PR/IR-London) Tel: +44 207 138 3204 Tim Blythe tim.blythe@blythewei Megan Ray megan.ray@blytheweig |
Posted at 27/9/2019 14:58 by pr100 I feel so sorry or John Peterson and his £18k loss on Afriag. He seems a thoroughly decent, honest and patient chap who deserved better. He hardly complains about it, acknowledging that much of the responsibility for his loss rests on his own shoulders.But all he did was believe the BS spouted by David Lenigas in "regulated" announcements. We are supposed to be able to believe these announcements and he won't be alone in swallowing the nonsense therein. The system is broken: regulators don't check deeply enough to be able to warrant the accuracy of RNS's. And the job of conducting due diligence as a private individual is never easy - especially when shareholders funds are allegedly invested in private companies in remote jurisdictions. Lenigas won't care about John. The roads to ruin are littered with the detritus of other Lenigas followers - in Afriag and dozens more confected companies. There has only ever been one winner in the Lenigas game. But on the other hand, there have been warnings a-plenty about Afriag - from me and others. If John dismissed them because others told him I had to have a vested interest in Afriag's demise, that's his own fault. The desire to bury your head in the sand if you are a Lenigas investor is understandable initially; but after a sustained period of value destruction and blatant lies, most of the followers see the light and bail out. John stayed too long and it cost him dearly. The only way to evaluate Lenigas RNS's is to assume from the get-go that they are a pack of lies which require you to prove the veracity of the outrageous claims therein before parting with any of your kids' inheritance. On this basis, Lenigas would have had zero investors and a huge body of PIs would be much wealthier today. This latest Apollon blag is just more of the same. Anyone who swallows it must seek help from others with more experience or more wisdom. Afriag is doomed. Salvage what you can. |
Posted at 21/7/2019 07:44 by pr100 "Apollon seem to have published some photos to allay my concerns about their facilities. Unfortunately, they show a tiny glasshouse with a handful of plants and no irrigation or growing infrastructure - and a "laboratory that obviously isn't a laboratory.Well, these two photos now seem to have been removed from the slideshow on the Doc's Place home page - together with all references to cannabis. It is now apparently just a B&B with a massage parlour. If the business plan has changed, surely investors should be told? |
Posted at 21/7/2019 07:29 by pr100 "8. Any credible peer-reviewed proof anywhere in the world that cannabis is an effective treatment for the following diseases and illnesses that AFJ claims to be able to treat with it: Prostate Cancer; Breast Cancer; Brain Cancer; Chronic Pain; Arthritis; Crohn’s Disease/Ulcerative Colitis; Glaucoma; HIV; Alzheimer’s; Lupus (SLE); Parkinson’s disease."So the above list of miracle cures has just been removed from the Apollon/Doc's Place website - which doesn't even mention cannabis any more. Now seems to be promoted as just a Bed & Breakfast - without any cannabis therapies - with Barnhill Jnr acting as the customer. This may be a step toward Legal, Decent, Honest & Truthful but it isn't the story Afriag PIs/investors were spun. |
Posted at 17/7/2019 17:34 by longrod Looking towards the future and not the past which I understand is fraught with a lot of historical financial pain I along with many other UK and international Investors have been quietly supporting some very unique research into various medical formulations for human ailments. The company has already identified 10 such formulations which it has trade marked and is producing at its licensed processing facility including "Apollon Cancer" "Apollon Seizure" etc etcThe company has a team of globally recognised physicians, oncologists, one brain surgeon, a homeopathic specialist and clinical pathologists that have worked together for decades. Dr. Barnhill invented machine vector learning a subject cited in more than 10,000 international peer reviewed medical and scientific publications and he and his team have previously identified, patented and subsequently sold to big Pharma treatments for melanoma, breast and prostate cancer. Its worth actually waiting for this. But if you decide not to it is of no matter because if you sell at these prices you sell to people who know and understand. I will most likely attract some initial criticism from some old afriag shareholders as they need somewhere to vent but as i said, this is about the future, not the past. Happy to discuss with sensible people. |
Posted at 17/7/2019 09:06 by pr100 Longrod, you're a card. If you have seen these things for yourself, post some photos. Surely there's nothing secret about showing off the facilities?And please link me to Dr Barnhill's published cannabis research and current patents. These are the basic things you should be showing to potential new investors to prove that it's not all smoke and mirrors. |
Posted at 16/7/2019 11:45 by pr100 Longrod, all potential investors should be shown *proof* that a company is worth investing in. Otherwise, it's like buying fluffy bears from a street market. You seem to place a lot of faith in the due diligence conducted by NEX and Afriag's lawyers - but they just don't dig that deep. They take on trust what they are told about the associate companies of proposed investees - especially if they are privately owned. So do auditors.So far, we have been told a load of hogwash about Apollon UK and Apollon Jamaica because none of it is verifiable. What we do know is that Doc's Place opened two branches in Jamaica in 2016/7 both of which closed down a year or two later. And we know that Dr Barnhill's global reputation is based on AI, not on medical cannabis. And that the patents he has filed over the years are owned by his former employers. And we know that, other than RNSs issued by Afriag, there has been precious little written about Apollon Jamaica and its pioneering work. If you ignore the advertorials in a strange magazine called Edibles, virtually nothing. And we know that they still aren't taking any bookings for this fantastic revival in Negril (none of which has been covered in the local media). Too much smoke and mirrors and not enough substance to make this a serious proposition so be careful with your cash. |
Posted at 16/7/2019 10:06 by pr100 Longrod, you could say that my scepticism is personal. I am sceptical about everything David Lenigas touches (even though I have never been an investor, thank god). But if you are better informed than me, please set my mind at rest. Any of the following would be most welcome:1. Any evidence, apart from a vague personal agreement, that Apollon Formularies Ltd (AFL) owns 49% of Apollon Formularies Jamaica (AFJ) and is entitled to receive 95% of its net profit (should it ever make any). 2. Any evidence, including photographs, that AFJ owns a cannabis laboratory and a cannabis cultivation greenhouse, as claimed. 3. Any evidence that AFJ owns any current patents. 4. Any evidence, including recent photographs, that Doc's Place Negril is up and running and open for business. 5. Any evidence that AFJ has an equity stake in Doc's Place Negril or is anything more than a franchise holder in a business which seemingly closed down a year ago. 6. Any evidence that AFJ has conducted scientific research and/or credible patient trials to prove the efficacy of its medical cannabis treatments. 7. Any evidence that AFJ has published peer reviewed scientific papers demonstrating the effectiveness of its cannabis treatments. 8. Any credible peer-reviewed proof anywhere in the world that cannabis is an effective treatment for the following diseases and illnesses that AFJ claims to be able to treat with it: Prostate Cancer; Breast Cancer; Brain Cancer; Chronic Pain; Arthritis; Crohn’s Disease/Ulcerative Colitis; Glaucoma; HIV; Alzheimer’s; Lupus (SLE); Parkinson’s disease. 9. Any evidence, other than the price Afriag paid for its shares, that AFL is worth £40m, or even £1m. 10. Any evidence that any David Lenigas public company has ever generated any value for its shareholders beyond brief P&D share price spikes - or that one has ever made a good investment on behalf of its shareholders. Thanks for your help. |
Posted at 11/7/2018 07:40 by cpap man 11 July 2018AfriAg Global PLC (“AfriAg Global” or the “Company” Update: Expansion of Investment Strategy to include Medical Cannabis AfriAg Global PLC, the London listed global food and logistics investment group, provides an update on its intention to seek shareholder approval to expand its investment strategy to include investments in the developing markets for medicinal cannabis derivatives, or related products. David Lenigas, AfriAg Global’s Chairman commented: “The legalised global cannabis industry is a fast-growing sector with many international governments now legalising the use of cannabis products for medical use. Since out last announcement on this matter, the Company has engaged experienced UK legal counsel as part of the process of gaining approvals from our regulators to actively engage in this very exciting sector and we now in active discussions with leading global experts in the medical cannabis field to join our advisory board.” The Company’s expanded investment strategy will include investments in companies, projects or products that are either progressing medicinal cannabis research and development; producing or cultivating medicinal cannabis; or commercialising or marketing medicinal cannabis and its derivatives. AfriAg will look to invest in companies and projects in jurisdictions which have well-developed and reputable laws and regulation for the research and production of medicinal cannabis and in jurisdictions that are signatories to the United Nation’s conventions on narcotics. The Company is likely to be an active investor within this sector and acquire control of certain target companies although it may also consider acquiring non-controlling shareholdings. The proposed investments to be made by the Company may be in either quoted or unquoted securities and made by direct acquisition of an interest in companies, partnerships or joint ventures, or direct interests in projects and can be at any stage of development. Accordingly, the Company’s equity interest in a proposed investment may range from a minority position to 100 per cent. ownership and a controlling interest. The Directors primary objective is to achieve the best possible value over time for Shareholders, primarily through capital growth. The Board believes that their collective experience, together with their extensive network of contacts, will assist them in the identification, evaluation and funding of appropriate investment opportunities within the medicinal cannabis space. When necessary, other external professionals will be engaged to assist in the due diligence on prospective targets and their management teams. The Directors will also consider appointing additional directors and /or advisors with relevant experience if the need arises. There will be no limit on the number of projects into which the Company may invest within this space, and the Company may invest in a number of propositions or in just one investment, which may be deemed to be a reverse takeover pursuant to Rule 58 of the NEX Exchange Rules. The Company may need to raise additional funds for these purposes and may use both debt and/or equity. It is anticipated that there may be opportunities to spin out businesses privately or via IPO where Shareholders may be able to benefit via distributions of cash and/or shares and/or rights to subscribe in listings. It is anticipated that the Company will hold investments for the medium to long term, although where opportunities exist for shorter term gains the Company may take advantage of such opportunities. If the Company takes a controlling stake, the acquisition could trigger a Reverse Takeover under Rule 57 of the NEX Exchange Rules. |
Posted at 27/6/2018 12:40 by pr100 Farce of an AGM. Where is the proof that Afriag Global own 40% of Afriag (Pty)?Directly leased truck fleet slashed to 42 while using sub-contractors if more needed. Lenigas must be joking when he said that this would improve margins. It will hurt margins which are already dangerously thin. And the "scale" story doesn't compute. They had "scale" when they had a large fleet of their own and it didn't generate any profits. With sub-contractors taking an increasing slice of the pie, there will be even less chance of generating any profits. The cannabis yarn is an admission of defeat - as well as a warning about an upcoming keep-the-lights-on fundraising. How else can Lenigas raise cash to invest in a new industry? And if anyone believes that Lenigas will be more transparent going forward, they are being naive and gullible. Lenigas doesn't do transparency. All in all, AFRI is a mismanaged disaster for minority investors and some PIs are rightly taking the chance to dump. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
